pharmacie et médicaments – Prise en charge du myélome multiple

This written question concerns the treatment of multiple myeloma, a type of blood cancer, and the associated pharmaceutical provisions. It seeks clarification on current policies and future strategies for managing this condition. The question addresses patients, healthcare providers, and the pharmaceutical industry. It aims to understand how access to effective treatments and medications for multiple myeloma is ensured and improved.